267 related articles for article (PubMed ID: 28284718)
41. JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis.
Yan J; Zhang Z; Yang J; Mitch WE; Wang Y
J Am Soc Nephrol; 2015 Dec; 26(12):3060-71. PubMed ID: 26032813
[TBL] [Abstract][Full Text] [Related]
42. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.
Sato T; Toki T; Kanezaki R; Xu G; Terui K; Kanegane H; Miura M; Adachi S; Migita M; Morinaga S; Nakano T; Endo M; Kojima S; Kiyoi H; Mano H; Ito E
Br J Haematol; 2008 May; 141(5):681-8. PubMed ID: 18397343
[TBL] [Abstract][Full Text] [Related]
43. STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma.
Coppo P; Gouilleux-Gruart V; Huang Y; Bouhlal H; Bouamar H; Bouchet S; Perrot C; Vieillard V; Dartigues P; Gaulard P; Agbalika F; Douay L; Lassoued K; Gorin NC
Leukemia; 2009 Sep; 23(9):1667-78. PubMed ID: 19421230
[TBL] [Abstract][Full Text] [Related]
44. The molecular mechanism of curcumol on inducing cell growth arrest and apoptosis in Jurkat cells, a model of CD4⁺ T cells.
Wang H; Wang Y; Jiang X; Wang Z; Zhong B; Fang Y
Int Immunopharmacol; 2014 Aug; 21(2):375-82. PubMed ID: 24877754
[TBL] [Abstract][Full Text] [Related]
45. Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.
Rivera-Munoz P; Laurent AP; Siret A; Lopez CK; Ignacimouttou C; Cornejo MG; Bawa O; Rameau P; Bernard OA; Dessen P; Gilliland GD; Mercher T; Malinge S
Blood Adv; 2018 Jul; 2(13):1616-1627. PubMed ID: 29986854
[TBL] [Abstract][Full Text] [Related]
46. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
Zhu F; Dai C; Fu Y; Loo JF; Xia D; Gao SP; Ma Z; Chen Z
Oncotarget; 2016 Feb; 7(8):9462-76. PubMed ID: 26843613
[TBL] [Abstract][Full Text] [Related]
47. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
48. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.
Wei J; Ma L; Li C; Pierson CR; Finlay JL; Lin J
Curr Cancer Drug Targets; 2019; 19(7):571-582. PubMed ID: 30332965
[TBL] [Abstract][Full Text] [Related]
49. [Expression and its significance of STAT3, STAT5, Survivin and Ki67 in nasal NK/T cell lymphoma].
Yue L; Cheng J; Zhang Pf; Lin G; Yi Z; Zhang R
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Oct; 20(20):931-3, 936. PubMed ID: 17225522
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma.
Amin HM; Medeiros LJ; Ma Y; Feretzaki M; Das P; Leventaki V; Rassidakis GZ; O'Connor SL; McDonnell TJ; Lai R
Oncogene; 2003 Aug; 22(35):5399-407. PubMed ID: 12934099
[TBL] [Abstract][Full Text] [Related]
51. Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.
Chen YW; Guo T; Shen L; Wong KY; Tao Q; Choi WW; Au-Yeung RK; Chan YP; Wong ML; Tang JC; Liu WP; Li GD; Shimizu N; Loong F; Tse E; Kwong YL; Srivastava G
Blood; 2015 Mar; 125(10):1589-600. PubMed ID: 25612622
[TBL] [Abstract][Full Text] [Related]
52. Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF-κB/P65 pathway.
Gao M; Liu L; Zhang X; Li Z; Zhang M
Environ Toxicol Pharmacol; 2021 Jul; 85():103639. PubMed ID: 33771682
[TBL] [Abstract][Full Text] [Related]
53. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling.
Ng SB; Selvarajan V; Huang G; Zhou J; Feldman AL; Law M; Kwong YL; Shimizu N; Kagami Y; Aozasa K; Salto-Tellez M; Chng WJ
J Pathol; 2011 Mar; 223(4):496-510. PubMed ID: 21294123
[TBL] [Abstract][Full Text] [Related]
54. JAK kinases overexpression promotes in vitro cell transformation.
Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
[TBL] [Abstract][Full Text] [Related]
55. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon.
Rosengren S; Corr M; Firestein GS; Boyle DL
Ann Rheum Dis; 2012 Mar; 71(3):440-7. PubMed ID: 22121136
[TBL] [Abstract][Full Text] [Related]
56. Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma.
Tsutsui M; Yasuda H; Suto H; Imai H; Isobe Y; Sasaki M; Kojima Y; Oshimi K; Sugimoto K
Int J Lab Hematol; 2010 Aug; 32(4):419-26. PubMed ID: 19968719
[TBL] [Abstract][Full Text] [Related]
57. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
58. Tetrandrine cardioprotection in ischemia-reperfusion (I/R) injury via JAK3/STAT3/Hexokinase II.
Zhang TJ; Guo RX; Li X; Wang YW; Li YJ
Eur J Pharmacol; 2017 Oct; 813():153-160. PubMed ID: 28822855
[TBL] [Abstract][Full Text] [Related]
59. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
60. Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.
Yoshida H; Kimura A; Fukaya T; Sekiya T; Morita R; Shichita T; Inoue H; Yoshimura A
Biochem Biophys Res Commun; 2012 Feb; 418(2):234-40. PubMed ID: 22252297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
